Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul.

Under CEO Richard Francis’ “Pivot to Growth” strategy, Teva Pharmaceutical Industries has undergone a significant ...

Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...

"Detect the SOS is a multi-stakeholder movement that brings together trusted voices, advocates, healthcare professionals and ...

Ro is bringing Serena Williams to the Super Bowl. Months after partnering with Williams, Ro has secured airtime at Super Bowl LX to showcase how the 23-time Grand Slam tennis champion’s life changed ...

With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, ...

About 1.8 million people used one or more of the 15 drugs through Medicare Part D or Part B between November 2024 and October 2025, the CMS said. The batch of 15 meds accounted for about $27 billion ...

After posting 16.2% revenue growth in the last financial year, Servier President Olivier Laureau said the company has moved ...

Regulatory authorities in China have cracked down on Sun Pharma’s rivastigmine-based Alzheimer’s disease treatment, halting ...

Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell ...

The drugmaker has recruited Will Forte, who appeared on “SNL” for nearly a decade in the aughts, perhaps most memorably as ...

But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good standing with physicians.